222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details

臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04009668 (ClinicalTrials.gov)	October 2, 2019	2/7/2019	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minim ...	Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerul ...	FSGS;MCD;Focal Segmental Glomerulosclerosis;Minimal Change Disease	Drug: adalimumab	University of Michigan	New York University	Recruiting	6 Years	70 Years	All	8	Phase 2	United States
2	NCT00814255 (ClinicalTrials.gov)	December 2008	22/12/2008	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	Novel Therapies for Resistant Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	Drug: Adalimumab;Drug: Lisinopril , losartan, and atorvastatin;Drug: galactose	New York University School of Medicine	University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney ...	Completed	1 Year	65 Years	All	32	Phase 2	United States;Canada
3	NCT00193648 (ClinicalTrials.gov)	July 2005	10/9/2005	Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)	Novel Therapies for Resistant FSGS	Focal Glomerulosclerosis	Drug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira)	North Shore Long Island Jewish Health System	University of North Carolina;The Cleveland Clinic	Completed	2 Years	40 Years	Both	21	Phase 1	United States

First Previous1Next Last